Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmigeneROCO:7595 -2.33%54 Days Payable is 41.60 as of Dec. 2025, which is 36% above its 10-year median of 30.64. GuruFocus rates ROCO:7595 with a GF Score™ of 54/100 and a GF Value™ of NT$24.76 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Pharmigene ranks worse than 64.92% on this metric.
Pharmigene's average Accounts Payable for the
six
months ended in Dec. 2025 was NT$20.0 Mil. Pharmigene's Cost of Goods Sold for the
six
months ended in Dec. 2025 was NT$87.6 Mil.
Hence, Pharmigene's Days Payable for the
six
months ended in Dec. 2025 was 41.60.
The historical rank and industry rank for Pharmigene's Days Payable or its related term are showing as below:
ROCO:7595'
s Days Payable Range Over the Past 10 Years
Min: 12.62 Med: 30.64 Max: 54.39
Current: 46.09
During the past 9 years, Pharmigene's highest Days Payable was 54.39. The lowest was 12.62. And the median was 30.64.
ROCO:7595's Days Payable is ranked worse than 64.92% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.48
vs ROCO:7595: 46.09
Pharmigene's Days Payable
declined
from Dec. 2024 (42.16) to Dec. 2025 (41.60).
It may suggest that Pharmigeneaccelerated paying its suppliers.
Pharmigene Days Payable Related Terms
Pharmigene Days Payable Historical Data
* Premium members only.
The historical data trend for Pharmigene's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7595 vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Pharmigene's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmigene Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pharmigene's Days Payable distribution charts can be found below:
* The bar in red indicates where Pharmigene's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Pharmigene's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmigene (ROCO:7595) has a Days Payable of 41.60 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pharmigene and its competitors. This is 36% above median its historical median of 30.64. Over the past decade, Pharmigene's Days Payable has ranged from 12.62 to 54.39. According to the industry distribution chart, Pharmigene ranks #124 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 64.9%.
Is Pharmigene's Days Payable too high?
Pharmigene's current Days Payable of 41.60 is 36% above median its 10-year median of 30.64. Over the past 10 years, this metric has ranged from a low of 12.62 to a high of 54.39. The Medical Diagnostics & Research industry median Days Payable is 64.48. Pharmigene's value of 41.60 is 35.5% below this industry median. Based on the distribution chart, Pharmigene ranks #124 out of 191 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Pharmigene has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pharmigene's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pharmigene ranks #124 out of 191 companies for Days Payable. This places Pharmigene in the lower half of its industry. The industry median Days Payable is 64.48. Pharmigene's value of 41.60 is 35.5% below this benchmark. Historically, Pharmigene's own Days Payable has ranged from 12.62 to 54.39 over the past decade. While the company's 10-year median is 30.64 vs. the industry median of 64.48, Pharmigene has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.48, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmigene's current Days Payable of 41.60 is 35.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pharmigene and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmigene's current Days Payable is 41.60, which is 36% above median its own 10-year median of 30.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmigene stock overvalued right now?
Based on GuruFocus' analysis, Pharmigene (ROCO:7595) is currently considered Possible Value Trap. The stock's GF Value™ is NT$24.76, compared to a current price of NT$6.30 — trading 74.6% below its estimated fair value. The current Days Payable is 41.60, which is 36% above median its 10-year median of 30.64 and 35.5% below the Medical Diagnostics & Research industry median of 64.48. Pharmigene's overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pharmigene (ROCO:7595), the current Days Payable is 41.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmigene (ROCO:7595) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmigene stock appears to be undervalued.
The current stock price of NT$6.30 is trading 74.6% below its estimated GF Value™ of NT$24.76.
GuruFocus considers Pharmigene to be Possible Value Trap.
Key valuation signals for ROCO:7595:
Days Payable: 41.60 (36% above median its 10-year median of 30.64)
GF Value™: NT$24.76 vs. price of NT$6.30 (74.6% below fair value)
Industry Position: 35.5% below the Medical Diagnostics & Research median (#124 of 191)
No single metric tells the full story. See the ROCO:7595 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmigene Inc is engaged in the development and sales of pharmaceutical genetic diagnostic products. Also, the company provides medical and drug testing services and equipment.
54GF Score
Get the complete analysis for ROCO:7595
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7595 has been successfully added to your 
